Entresto Denied by Insurance? How to Appeal

Entresto (sacubitril/valsartan) is a cornerstone therapy for heart failure with reduced ejection fraction (HFrEF) — and it's frequently denied because it costs $500–$600/month while generic ACE inhibitors cost $5–$15/month. If your cardiologist prescribed Entresto and your insurance denied it, here's how to build a winning appeal.

Why Insurers Deny Entresto

ACE inhibitor/ARB step therapy. The most common denial reason: the plan requires trial and failure of a generic ACE inhibitor (lisinopril, enalapril, ramipril) or ARB (losartan, valsartan) before approving Entresto. However, Entresto is not simply a "better ACE inhibitor" — it's a mechanistically different dual drug with proven superiority.

EF threshold not documented. Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization requires documented ejection fraction (typically EF ≤40% for HFrEF indication) from echocardiogram or other imaging.

Not on GDMT first. Insurers may require that the patient be on optimal Guideline-Directed Medical Therapy (GDMT) — beta-blocker + ACE/ARB/ARNI + MRA + SGLT2 inhibitor — before or concurrent with Entresto.

HFpEF indication: Entresto has an FDA approval for HFmrEF/HFpEF (EF ≥45% with elevated BNP), but coverage for this broader indication is less uniform.

Clinical Arguments for Entresto

The PARADIGM-HF Trial Evidence

The landmark PARADIGM-HF trial (NEJM 2014) compared Entresto vs. enalapril in 8,442 patients with HFrEF (EF ≤40%):

• 20% relative risk reduction in cardiovascular death or HF hospitalization (p<0.001)
• 16% reduction in cardiovascular death
• 21% reduction in HF hospitalizations
• NNT: 21 to prevent one cardiovascular death or HF hospitalization
• Trial stopped early due to overwhelming benefit

This is one of the strongest trial results in modern cardiology. The argument that enalapril (generic ACE inhibitor) is "equivalent enough" is directly contradicted by this trial.

ACC/AHA Heart Failure Guidelines

2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure:

• Class I recommendation (Level A evidence): ARNI (sacubitril/valsartan) is recommended to reduce morbidity and mortality in patients with chronic symptomatic HFrEF (EF ≤40%)
• The guideline recommends ARNI instead of (not in addition to) an ACE inhibitor or ARB
• Step therapy from ACE inhibitor to Entresto is clinically reasonable; requiring ongoing treatment failure on ACE inhibitor before switching is not aligned with the guideline

Additional Evidence

TRANSITION Trial: Demonstrated Entresto can be safely initiated in-hospital or at 1–2 weeks post-discharge following acute decompensated HF.

PARADIGM-HF Subgroups: Benefit was consistent across all subgroups including patients already on target doses of enalapril — meaning "try harder on enalapril" is not the answer.

Building Your Appeal Letter

Required Documentation

Have your cardiologist provide:

1. Echo or cardiac MRI documenting EF (EF ≤40% for HFrEF; EF ≥45% with elevated BNP/NT-proBNP for HFpEF/HFmrEF)
2. NYHA functional class (II, III, or ambulatory IV)
3. Current medication list showing GDMT compliance (beta-blocker, MRA, SGLT2i if indicated)
4. Prior ACE inhibitor/ARB history — if applicable, document trial and failure or contraindication
5. NT-proBNP or BNP levels demonstrating HF burden
6. Hospitalization history for HF exacerbations

ACE Inhibitor Contraindications or Intolerance

If the patient previously had an ACE inhibitor-induced cough (very common — up to 20% of patients), angioedema, or renal failure, document this explicitly. ACE inhibitor intolerance is a direct path to Entresto coverage without step therapy.

Address the HFpEF Indication if Relevant

For patients with EF ≥45%:

• Document elevated NT-proBNP (≥400 pg/mL in outpatients; ≥900 pg/mL during hospitalization) or BNP (≥100 pg/mL)
• Cite the PARAGON-HF trial and subsequent FDA approval for HFpEF/HFmrEF
• Note that ACC/AHA guidelines give this a Class IIb recommendation (Level B)

Step-by-Step Appeal Process

1. Get denial with PA criteria cited
2. Request echo results to be included in the appeal record
3. Physician letter citing PARADIGM-HF data, ACC/AHA Class I recommendation
4. Request peer-to-peer review — cardiologist-to-cardiologist reviews resolve most Entresto denials
5. File internal appeal with all documentation
6. External Independent Review: Complete Guide" class="auto-link">External review if internal appeal fails

Step Therapy Override Strategy

If your state has step therapy override laws (45+ states as of 2026):

Step therapy may be overridden when:

• The patient has previously failed the required drug (prior ACE inhibitor failure)
• The required drug is contraindicated (ACE inhibitor cough, angioedema, hyperkalemia, renal dysfunction)
• Clinical guidelines recommend the requested drug as preferred therapy (ACC/AHA Class I, Level A)
• Requiring the step therapy drug would cause patient harm

Sample Appeal Language

"I am appealing the denial of Entresto (sacubitril/valsartan) [dose] for heart failure with reduced ejection fraction (EF [X]%, documented by echo [date]). My cardiologist, Dr. [Name], has determined that Entresto is the appropriate guideline-directed medical therapy for this patient.

The 2022 ACC/AHA/HFSA Heart Failure Guidelines give Entresto a Class I recommendation (Level A) for HFrEF — the strongest evidence level in medicine. The landmark PARADIGM-HF trial demonstrated a 20% relative risk reduction in CV death or HF hospitalization compared to enalapril, establishing Entresto's superiority over ACE inhibitors. Requiring additional trial of generic ACE inhibitors conflicts with established clinical guidelines and denies this patient evidence-based therapy. I respectfully request reversal of this denial."

Fight Back With ClaimBack

ClaimBack generates Entresto appeal letters citing PARADIGM-HF data, ACC/AHA Class I guideline recommendations, and the clinical documentation required for your specific HF phenotype.

Free analysis. Appeal letter from USD 12.

Related Reading

• Prior Authorization Denied? How to Appeal
• What Is Medical Necessity and How to Prove It
• Common Reasons Insurance Claims Are Denied